Back to News
Market Impact: 0.2
Lake Street Initiates Coverage of Spruce Biosciences at Buy
Source: Nasdaq
Healthcare & BiotechAnalyst Insights
Lake Street initiated coverage of Spruce Biosciences (NASDAQCM: SPRB) on September 17, 2026, with a Buy recommendation. The positive analyst initiation highlights investor interest in Spruce's late-stage rare-endocrine therapy pipeline, though the article provides no price target, financial estimates, or clinical-catalyst details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SPRB0.45
More News
- Synaptics SVP Lisa Bodensteiner sells $30,938 in stock
- Synaptics VP & corporate controller Esther Song sells $5,835 in stock
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Activist Jana Pushes Cooper Cos. to Replace CEO, Board Chair
- Nike parts ways with Kylian Mbappé, soccer superstar signs with On
- ‘No one knows what is in these deals’: Trump set to announce new Medicaid drug pricing model amid affordability concerns
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis